Currently submitted to: JMIR Preprints
Date Submitted: Apr 15, 2021
Open Peer Review Period: Apr 14, 2021 - Mar 30, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An overview of COVID-19 induced gastrointestinal symptoms and liver dysfunction
ABSTRACT
The ongoing pandemic of COVID-19 beginning in December 2019 has caused widespread devastation to many individuals worldwide. Gastrointestinal manifestations and complications associated with SARS-CoV-2 are some of the less discussed implications of this virus. The initial gastrointestinal symptoms noted in COVID-19 patients are mainly diarrhea, nausea, poor appetite, anorexia, vomiting, diarrhea, and abdominal pain, as well as new onset of hepatic injury. Additionally, patients with a prior history of hepatic comorbidities have increased risk of progression to severe COVID-19. Presently, real-time reverse transcription polymerase chain reaction (RT-PCR), serological based tests, and imaging are used to achieve a definitive diagnosis. The current management of COVID-19 is supportive care along with antiviral, anti-inflammatory and analgesic therapy. The use of microbiota transplantation for COVID-19 management is also discussed. The importance of this article is to enlighten the overall understanding of COVID-19 induced gastrointestinal and liver pathophysiology, diagnosis, management, and prognosis.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.